Levodopa/Carbidopa/Entacapone Rivopharm (Carbidopa, Entacapone, Levodopa)

The combination works by delivering levodopa, which is converted to dopamine in the brain, while carbidopa blocks peripheral conversion of levodopa, increasing its availability to the central nervous system. Entacapone inhibits the COMT enzyme, slowing levodopa breakdown and prolonging its therapeutic action.

The specific dose and dosing schedule are determined by the prescribing physician based on the individual’s disease stage, response to therapy, and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for use in pregnancy and lactation are limited, and the product is generally classified as contraindicated or to be used only if the potential benefit justifies the potential risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with levodopa alone, the addition of carbidopa and entacapone improves central dopamine delivery and extends the drug’s half‑life, reducing off‑periods. It offers a more stable symptom control than some other adjuncts, but individual response varies, and choice of therapy depends on patient‑specific factors.

The tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Levodopa/Carbidopa/Entacapone is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets are swallowed whole with a full glass of water, and the dosing frequency is determined by the prescriber based on therapeutic response.

Serious risks include severe hypotension, neuroleptic malignant syndrome, severe allergic reactions, and psychiatric effects such as depression, hallucinations, or suicidal thoughts. Patients should be monitored closely for these events, and any concerning symptoms should prompt immediate medical evaluation.

Patients with known hypersensitivity to levodopa, carbidopa, entacapone, or any excipients should avoid the product. It is also contraindicated in individuals taking non‑selective MAO inhibitors. Caution is advised in patients with severe cardiovascular disease, hepatic impairment, or a history of psychiatric disorders.